Previous 10 | Next 10 |
Mercurity Fintech Holding (MFH) +65%. Fast Radius (FSRD) +21%. Nikola (NKLA) +18% after investor event. Femasys (FEMY) +13%. BiondVax Pharmaceuticals (BVXV) +13% on research pact to develop nanosized antibody therapies. Incannex Healthcare (IXHL) +12%. D-MARKET Elektronik&...
3 Penny Stocks That You Should Add to Your Watchlist in April If you’re thinking about investing in penny stocks, you’re definitely not alone. A lot of people invest in penny stocks because they believe it’s a good way to make money. And, for the most part, that...
If you’re looking for the most exciting way to make money in the stock market today, penny stocks should be at the top of your list. These high-flying, low-priced names have become a mainstay for day traders and investors alike. The idea of “getting in early” tends to a...
United Time Technology (UTME) +46%. BT Brands (BTBD) +37%. O2Micro International (OIIM) +31%. Anaplan (PLAN) +28% Thoma Bravo agrees to buy Anaplan for $10.7B. Vinco Ventures (BBIG) +22%. Marine Petroleum (MARPS) +21%. Mullen Automotive (MULN) +20%. Cuentas (CUEN) +14% pa...
Gainers: BioVie (BIVI) +16%. Progenity (PROG) +16%. Kezar Life Sciences (KZR) +14%. Codiak BioSciences (CDAK) +13%. Ensysce Biosciences (ENSC) +10%. Losers: Nymox Pharmaceutical (NYMX) -29%. HTG Molecular Diagnostics (HTGM) -14%. Zhongchao (ZC...
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended ...
Hycroft Mining (NASDAQ:HYMC) +84% AMC Entertainment is buying 22% of Hycroft Mining Holding. Incannex Healthcare (NASDAQ:IXHL) +66%. Excellon Resources (NYSE:EXN) +23%. Hollysys Automation Technologies (NASDAQ:HOLI) +12%. Anavex Life Sciences (NASDAQ:AVXL) +9% posts mid-st...
Progenity (NASDAQ:PROG) announced progress with its clinical device performance study plan, evaluating device function and safety of its drug delivery system (DDS) capsule. The company said its first clinical device performance study evaluated the safety and tolerability of its DDS capsule an...
Clinical Device Performance Study in Healthy Volunteers Demonstrated Accurate Localization and Delivery A Clinical Device Performance Study in Patients with Ulcerative Colitis is Now Recruiting SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasd...
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of three abstracts on the treatment of IBD and microbiome sampling ...
News, Short Squeeze, Breakout and More Instantly...
Progenity Inc. Company Name:
PROG Stock Symbol:
NASDAQ Market:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...